U.S. markets open in 13 minutes

Bristol-Myers Squibb Company (BMY)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
61.33-0.77 (-1.24%)
At close: 4:00PM EST

61.65 +0.32 (0.52%)
Pre-Market: 9:16AM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close62.10
Open62.03
Bid61.55 x 900
Ask61.88 x 800
Day's Range61.26 - 62.70
52 Week Range45.76 - 67.16
Volume13,229,819
Avg. Volume11,910,188
Market Cap137.409B
Beta (5Y Monthly)0.62
PE Ratio (TTM)N/A
EPS (TTM)-3.99
Earnings DateMay 05, 2021 - May 10, 2021
Forward Dividend & Yield1.96 (3.20%)
Ex-Dividend DateDec 31, 2020
1y Target Est75.13
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 3 Top Stocks That'll Make You Richer in March (and Beyond)
    Motley Fool

    3 Top Stocks That'll Make You Richer in March (and Beyond)

    Growth stocks increase their sales by a double-digit percentage, are concerned with gobbling up market share, and aren't too focused on generating a profit. Meanwhile, value stocks are companies that have forward price-to-earnings multiples or price-to-earnings-growth ratios (PEG ratio) below the average of their industry or the broader market.

  • Agios' (AGIO) Q4 Loss In Line, Revenues Surpass Estimates
    Zacks

    Agios' (AGIO) Q4 Loss In Line, Revenues Surpass Estimates

    Agios' (AGIO) loss meets estimates in the fourth quarter of 2020 while revenues beat the same. Sale of leukemia drug, Tibsovo, rise both sequentially as well as year over year. Shares down.

  • Is Bristol Myers Stock A Buy As Shares Flounder After Fourth-Quarter Beat?
    Investor's Business Daily

    Is Bristol Myers Stock A Buy As Shares Flounder After Fourth-Quarter Beat?

    Bristol Myers Squibb topped fourth-quarter expectations in February and cancer drug Opdivo returned to growth. But BMY stock floundered following the report. Is Bristol Myers stock a buy?